{"filing":{"accession_number":"0001193125-26-346855","cik":"0001701108","ticker":"SPRO","company_name":"Spero Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"d69249d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249d8k.htm"},"events":[{"id":27188,"run_id":24761,"accession_number":"0001193125-26-346855","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The company announced second quarter 2026 financial results on August 12, 2026, including net loss of $9.6 million (vs. $1.7 million in Q2 2025), zero revenue (vs. $14.2 million in Q2 2025), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 and includes condensed consolidated balance sheet and statements of operations. While the filing also covers business highlights (SP001 license agreement, Utebzi FDA approval, royalty financing, and CMO appointment), the Item 2.02 section is explicitly focused on financial results for the quarter ended June 30, 2026.","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28610,"accession_number":"0001193125-26-346855","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company announced second quarter 2026 financial results on August 12, 2026, including net loss of $9.6 million (vs. $1.7 million in Q2 2025), zero revenue (vs. $14.2 million in Q2 2025), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 and includes condensed consolidated balance sheet and statements of operations. While the filing also covers business highlights (SP001 license agreement, Utebzi FDA approval, royalty financing, and CMO appointment), the Item 2.02 section is explicitly focused on financial results for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:13:08.879390+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28610,"accession_number":"0001193125-26-346855","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company announced second quarter 2026 financial results on August 12, 2026, including net loss of $9.6 million (vs. $1.7 million in Q2 2025), zero revenue (vs. $14.2 million in Q2 2025), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 and includes condensed consolidated balance sheet and statements of operations. While the filing also covers business highlights (SP001 license agreement, Utebzi FDA approval, royalty financing, and CMO appointment), the Item 2.02 section is explicitly focused on financial results for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:13:08.879390+00:00","company_name":"Spero Therapeutics, Inc.","ticker":"SPRO","filing_date":"2026-08-12"}]}